Ruxolitinib And interferon-Α2 combination therapy for patients with polycythemia vera or myelofibrosis: A Phase II study
Last Updated: Monday, June 29, 2020
Final 2-year data from the phase 2 COMBI trial of ruxolitinib plus low-dose pegylated interferon-α2 reported a remission rate of 31% among patients with polycythemia vera and 44% among those with myelofibrosis, along with decreased symptom burden and acceptable toxicity.
Advertisement
News & Literature Highlights